| Description: |
13(E)-Labd-13-ene-8alpha,15-diol shows antiviral and anticancer activity, it shows strong anti-HRV2 and HRV3 activity with a 50% inhibitory concentration (IC50) of 2.68 and 0.87 microg/mL,respectively; it also exhibits antilung and antilaryngeal cancer activities against A549 and Hep2 cells.13(E)-Labd-13-ene-8α,15-diol inhibits the growth of the gram-positive bacteria (Staphylococcus aureus, Bacillus cereus and Listeria monocytogenes) and gram-negative bacteria (Vibrio parahaemolyticus, Escherichia coli and Salmonella enteritidis) with a range of minimum inhibitory concentration (MIC) values from 0.092 to 0.598 mg/mL and gram-negative bacteria are more sensitive to the compound (MIC, 0.092 mg/mL). |
| In vitro: |
| Phytother. Res.,2010 Feb;24(2):169-74. | | Antiviral and anticancer activities of 13(E)-labd-13-ene-8alpha,15-diol isolated from Brachyglottis monroi.[Pubmed: 19504469 ] |
METHODS AND RESULTS:
The antiviral activity of 13(E)-labd-13-ene-8alpha,15-diol (Labd-13-ene-8,15-diol,1), isolated from Brachyglottis monroi, was examined against human rhinovirus 2 (HRV2) and 3 (HRV3), and the anticancer activity on human cancer cells (A549 and Hep2). Compound (1) showed strong anti-HRV2 and HRV3 activity with a 50% inhibitory concentration (IC(50)) of 2.68 and 0.87 microg/mL, respectively, and a 50% cytotoxicity concentration (CC(50)) of 59.45 microg/mL. Ribavirin only showed anti-HRV3 activity with an IC(50) of 30.48 microg/mL and a CC(50) > 100 microg/mL. The addition of compound (1) to HRV-infected HeLa cells directly reduced the formation of visible cytopathic effect (CPE) and it directly interacted with HRV particles. Furthermore, A549 and Hep2 cells incubated with 32 microg/mL of compound (1) for 48 h exhibited antilung and antilaryngeal cancer activities, with a viability of less than 50%.
CONCLUSIONS:
These results suggest that compound (1) may be used as a potential antiviral and anticancer agent. | | J. Appl. Biol. Chem.,2013, 56(1):581-90. | | Anticancer and Antimicrobial Activities of 13(E)-labd-13-ene-8α,15-diol from Brachyglottis monroi[Reference: WebLink] | In a previous study, we reported that 13(E)-labd-13- ene-8α, 15-diol (Labd-13-ene-8,15-diol ,13E) possesses antiviral and anticancer activities.
METHODS AND RESULTS:
In this study, the anticancer and antimicrobial activities of 13(E) were evaluated against 4 cancer cell lines and 6 bacteria. 13(E) showed inhibitory effect on a variety of cancer cell lines. The IC50 values was 8.3-21.3 μg/mL. 13(E) was the most effective growth inhibitor of murine leukaemia cell lines P388, producing approximately 8.3 μg/mL of IC50 in the cytopathic effect (CPE) method. 13(E) also inhibited the growth of the gram-positive bacteria (Staphyl℃℃cus aureus, Bacillus cereus and Listeria mon℃ytogenes) and gram-negative bacteria (Vibrio parahaemolyticus, Escherichia coli and Salmonella enteritidis) with a range of minimum inhibitory concentration (MIC) values from 0.092 to 0.598 mg/mL and gram-negative bacteria were more sensitive to the compound (MIC, 0.092 mg/mL). |
|
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)
